Log in

NASDAQ:QDELQuidel Stock Price, Forecast & News

$156.89
-2.99 (-1.87 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$156.15
Now: $156.89
$164.44
50-Day Range
$98.73
MA: $153.59
$208.95
52-Week Range
$52.49
Now: $156.89
$210.81
Volume628,682 shs
Average Volume653,417 shs
Market Capitalization$6.59 billion
P/E Ratio76.53
Dividend YieldN/A
Beta1.13
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Read More
Quidel logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:QDEL
CUSIP74838J10
Phone858-552-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$534.89 million
Cash Flow$4.00 per share
Book Value$13.44 per share

Profitability

Net Income$72.92 million

Miscellaneous

Employees1,250
Market Cap$6.59 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive QDEL News and Ratings via Email

Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.

Quidel (NASDAQ:QDEL) Frequently Asked Questions

How has Quidel's stock been impacted by COVID-19 (Coronavirus)?

Quidel's stock was trading at $89.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, QDEL shares have increased by 74.9% and is now trading at $156.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Quidel?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Quidel.

When is Quidel's next earnings date?

Quidel is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Quidel.

How were Quidel's earnings last quarter?

Quidel Co. (NASDAQ:QDEL) posted its quarterly earnings data on Wednesday, February, 12th. The company reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.82 by $0.18. The firm had revenue of $152.20 million for the quarter, compared to analyst estimates of $148 million. Quidel had a net margin of 15.73% and a return on equity of 23.69%. The company's revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.80 EPS. View Quidel's earnings history.

What price target have analysts set for QDEL?

5 equities research analysts have issued 12 month price targets for Quidel's shares. Their forecasts range from $75.00 to $170.00. On average, they expect Quidel's share price to reach $117.00 in the next twelve months. This suggests that the stock has a possible downside of 25.4%. View analysts' price targets for Quidel.

Has Quidel been receiving favorable news coverage?

Headlines about QDEL stock have been trending negative on Friday, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Quidel earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutQuidel.

Are investors shorting Quidel?

Quidel saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 2,800,000 shares, an increase of 40.7% from the April 15th total of 1,990,000 shares. Based on an average daily volume of 522,400 shares, the short-interest ratio is currently 5.4 days. Currently, 7.6% of the shares of the company are short sold. View Quidel's Current Options Chain.

Who are some of Quidel's key competitors?

What other stocks do shareholders of Quidel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quidel investors own include NVIDIA (NVDA), Shopify (SHOP), Netflix (NFLX), Teladoc Health (TDOC), Trade Desk (TTD), Alibaba Group (BABA), Gilead Sciences (GILD), Twilio (TWLO), Adobe (ADBE) and Okta (OKTA).

Who are Quidel's key executives?

Quidel's management team includes the following people:
  • Mr. Douglas C. Bryant, Pres, CEO & Director (Age 61)
  • Mr. Randall J. Steward, Chief Financial Officer (Age 65)
  • Mr. Robert J. Bujarski, Sr. VP of Bus. Devel. & Gen. Counsel (Age 51)
  • Dr. Werner Kroll, Sr. VP of R&D (Age 62)
  • Mr. Edward Keith Russell, Sr. VP of Global Commercial Operations (Age 51)

What is Quidel's stock symbol?

Quidel trades on the NASDAQ under the ticker symbol "QDEL."

Who are Quidel's major shareholders?

Quidel's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (11.34%), BlackRock Inc. (6.26%), Fred Alger Management LLC (4.83%), ArrowMark Colorado Holdings LLC (2.11%), State Street Corp (2.07%) and New York State Common Retirement Fund (1.61%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View institutional ownership trends for Quidel.

Which institutional investors are selling Quidel stock?

QDEL stock was sold by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, ArrowMark Colorado Holdings LLC, Investment Management of Virginia LLC, Gabelli Funds LLC, Morgan Stanley, Morgan Stanley, Massachusetts Financial Services Co. MA, and New York State Common Retirement Fund. Company insiders that have sold Quidel company stock in the last year include Douglas C Bryant, Edward Keith Russell, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, and Werner Kroll. View insider buying and selling activity for Quidel.

Which institutional investors are buying Quidel stock?

QDEL stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Invesco Ltd., GW&K Investment Management LLC, JPMorgan Chase & Co., Sandler Capital Management, Federated Hermes Inc., Mackay Shields LLC, and Geode Capital Management LLC. View insider buying and selling activity for Quidel.

How do I buy shares of Quidel?

Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quidel's stock price today?

One share of QDEL stock can currently be purchased for approximately $156.89.

How big of a company is Quidel?

Quidel has a market capitalization of $6.59 billion and generates $534.89 million in revenue each year. The company earns $72.92 million in net income (profit) each year or $2.73 on an earnings per share basis. Quidel employs 1,250 workers across the globe.

What is Quidel's official website?

The official website for Quidel is www.quidel.com.

How can I contact Quidel?

Quidel's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 858-552-1100 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.